Risk‐adapted stereotactic body radiotherapy for patients with cervical spinal metastases

Owing to the complex anatomical structure and biomechanics, the current standard palliative treatments for cervical spinal metastases are associated with a high risk of recurrence and complications. Stereotactic body radiotherapy (SBRT) can provide radical dose to tumors while protecting normal organs to the maximum extent. However, the efficacy and safety of SBRT for cervical spinal metastases is not well characterized. Data from 71 patients with cervical spine metastases who were treated with SBRT using CyberKnife between 2006 and 2021 were obtained from our prospectively maintained database. Primary endpoint was pain response at 12 weeks following SBRT completion; secondary endpoints included local control (LC), overall survival (OS), and adverse events. Standard‐risk patients were planned to receive 30 Gy (range 21–36) with median fractions of 3 (range 1–3) and high‐risk patients 35 Gy (range 24–50) with median fractions of 5 (range 4–5) according to the spinal cord and esophagus dose constraints. The median follow‐up time was 17.07 months (range 3.1–118.9). After 12 weeks of SBRT completion, 54 (98.2%) of 55 patients with baseline pain achieved pain response and 46 (83.6%) achieved complete pain response. LC rates were 93.1% and 90% at 1 year and 2 year, respectively. The 1‐year and 2‐year OS rates were 66.2% and 37.4%, respectively. Eight patients experienced grades 1–4 adverse events (six vertebral compression fracture [VCF], five of them had VCF before SBRT; and two hemiparesis). No grade 5 adverse events were observed. Therefore, risk‐adapted SBRT for cervical spine metastases achieved high pain control and LC rates with acceptable adverse events.